CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled
Drug / intervention
omalizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00949078
NCT00949078Phase 2Completed
CompareCT.gov

Effects of Omalizumab on Peanut Allergen Induced Cellular and Clinical Responses in Peanut Allergic Adults

Johns Hopkins University·interventional·Posted Jul 30, 2009·Updated Jul 12, 2017

In Brief

A Phase 2 clinical trial evaluating omalizumab for Food Allergy and Peanut Allergy. Completed, enrolled 51 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if treatment with omalizumab (Xolair, anti-IgE) can eliminate or reduce symptoms of peanut allergy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFood Allergy, Peanut Allergy
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 30, 2009
Enrollment StartJul 1, 2009
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 16.9 years ago

Interventions

omalizumabdrug

omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE